Quintiles Rated Industry Leader and Highest in Service Quality in Phase II/III Clinical Research

Biopharma Recognizes Quintiles as the Leader in Customer Loyalty Among Large Clinical Research Organizations (CROs) in Quality Benchmarking Report

RESEARCH TRIANGLE PARK, N.C. - Wednesday, May 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- Quintiles is the industry leader that best differentiates itself on service quality in Phase II/III clinical research, according to 157 pharmaceutical and biotechnology professionals who responded to Industry Standard Research’s (ISR) 2013 CRO Quality Benchmarking Report – Phase II/III. Respondents also rated Quintiles as the leader among large CROs for customer loyalty, defined by overall satisfaction, willingness to recommend and likelihood to use Quintiles again.

“We are deeply committed to helping our customers increase their probability of success at every stage of the product lifecycle,” said Paula Brown Stafford, President, Clinical Development at Quintiles. “We are delighted to see that our leadership and commitment to both quality and customer satisfaction are recognized by the industry.”

According to the report:

    Quintiles is the best Phase II/III clinical research service provider at differentiation based on service quality;
    Quintiles leads large CROs in customer loyalty and is the most cited industry leader;
    Quintiles most consistently meets customer expectations, and is the leader among large CROs in exceeding expectations for global reach, breadth of services, local regulatory knowledge, commercial market knowledge and the ability to consistently meet “First Patient In” timelines.

Survey respondents also recognized Quintiles as a leader among large CROs for meeting customer expectations for real-time access to data. Quintiles is committed to transforming drug development through its data and proprietary knowledge engine, Quintiles Infosario®, an innovative solution that seamlessly integrates data, Quintiles’ systems, processes and therapeutic expertise to help customers make faster, more informed decisions.

This recognition comes on the heels of Quintiles’ award for Best CRO in Vaccine Industry Excellence presented in April 2013 at the World Vaccine Congress. More information about the ISR report is available at http://www.isrreports.com/industry-reports/2013-cro-quality-benchmarking-phase-ii_iii-service-providers.

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes.

Click here to subscribe to Mobile Alerts for Quintiles.

Contacts

Quintiles

Mari Mansfield, Media Relations

+1-919-998-2639

mobile: +1-919-259-3298

mari.mansfield@quintiles.com



Karl Deonanan, Investor Relations

+1-919-998-2789

InvestorRelations@quintiles.com